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Edited by Miguel De la RosaAbstract Fibroblast growth factor (FGF) receptor (FGFR)
consists extracellularly of three immunoglobulin (Ig) modules
(Ig1–3). Currently, there are two competing models (symmetric
and asymmetric) of the FGF–FGFR–heparin complex based on
crystal structures. Indirect evidence exists in support of both
models. However, it is not clear which model is physiologically
relevant. Our aim was to obtain direct, non-crystallographic evi-
dence in support of them. We found by nuclear magnetic reso-
nance that Ig2 could bind to FGF1 not only via the primary
site (present in both models), but also via the secondary site
(present only in the symmetric model). Thus, our data support
the symmetric model.
 2008 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Fibroblast growth factor (FGF) receptors (FGFR) are a
family of receptor protein tyrosine kinases, which regulate a
multitude of cellular processes including cell proliferation,
migration, diﬀerentiation and survival (for review, see [1,2]).
They interact with various ligands, such as FGFs [3], hepa-
rin/heparan sulfate proteoglycans (HS) and neural cell adhe-
sion molecules [4–6]. The FGFR-ligand interaction results in
receptor dimerization and activation of the tyrosine kinase do-
main, which triggers the downstream cell signaling.
It was found that HS proteoglycans are required for FGF
signaling [7] and the high-aﬃnity FGF–FGFR interactionAbbreviations: FGF, ﬁbroblast growth factor; FGFR, ﬁbroblast
growth factor receptor; HS, heparin/heparan sulfate proteoglycans;
HSQC, heteronuclear single quantum correlation; Ig, immunoglobu-
lin; NMR, nuclear magnetic resonance; NTA, nitrilotriacetic acid;
PBS, phosphate buﬀered saline; SPR, surface plasmon resonance
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doi:10.1016/j.febslet.2008.08.033[21,22]. Based on this, several models of FGFR dimerization
were proposed, which involved the FGFR immunoglobulin
(Ig) modules 2 and 3. The FGFR Ig1 module (structure re-
cently determined by Kiselyov et al. [8]) was found to have a
regulatory function [9] by binding to the Ig2 module [10]. Crys-
tallographic studies suggested two fundamentally diﬀerent
models of FGFR dimerization. Plotnikov et al. [11] and
Schlessinger et al. [12] proposed a so-called symmetric ‘‘two-
end’’ model. In this model, heparin interacts with both FGF
and FGFR within each 1:1 FGF:FGFR complex. Heparin
also interacts with FGFR of the adjoining 1:1 FGF:FGFR
complex. There is also an interaction between FGFs and
FGFRs of the adjoining complexes via primary (in Ig2, Ig3)
and secondary (in Ig2) sites as well as a direct interaction be-
tween the Ig2 modules of the two receptors. Pellegrini et al.
[13] proposed a second model, often called an asymmetric
model. The main feature of the model is a heparin bridge be-
tween trans-oriented FGFs. In this model, each FGF binds
only to one FGFR in the dimer through the primary site
and there are no direct receptor-receptor contacts, and no
FGF–FGFR interaction through the secondary site. Further-
more, there are absolutely no protein–protein contacts be-
tween the two FGF–FGFR complexes and the dimer is
stabilized solely by heparin. It should be noted that in the sym-
metric model, the Ig2 module interacts with FGF through its
primary and secondary sites, whereas in the asymmetric model
– only through the primary site. Since the contacts identiﬁed
by crystallography may be artifacts due to crystal packing, it
is important to validate the presence of these contacts in solu-
tion by other methods. Indirect evidence has been obtained in
favor of both models. Ibrahimi et al. [14] showed that muta-
tions in the secondary site (present only in the symmetric mod-
el) reduced FGF10 signaling, thus supporting the symmetric
model and arguing against the asymmetric model. However,
mass spectroscopy and gel ﬁltration analysis of the ternary
complex indicates that both types of complexes could be
formed in solution [15–17].
Here we studied the interaction between the FGFR Ig2 mod-
ule and FGF in solution by nuclear magnetic resonance
(NMR) with an aim to obtain a direct and non-crystallo-
graphic evidence to conﬁrm one of the two competing models.blished by Elsevier B.V. All rights reserved.
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the Ig2 module bound to FGF with a Kd value of 39 nM and
demonstrated that the module bound to FGF not only via the
primary but also the secondary site, which is only present in
the symmetric model. Thus, our data support the symmetric
model of the FGFR ternary complex.2. Materials and methods
2.1. Production and puriﬁcation of recombinant proteins
The Ig2 module of mouse FGFR1 consists of a His-tag,
AGHHHHHH, and amino acids 140–251 (Swissprot P16092). The
Ig2 module was produced as previously described [5]. In brief, the pro-
tein was expressed in KM71 strain of yeast Pichia pastoris (Invitrogen).
For the 15N-labeled protein 15N-labeled ammonium sulfate was used
as a nitrogen source. After expression, the supernatant (which contains
protein) was loaded on an aﬃnity chromatography column (Ni2+-
nitrilotriacetic acid (NTA) resin, Qiagen, Holland) and washed over-
night with 800 ml. of the 20% glycerin and 1 MNaCl in phosphate buf-
fered saline (PBS) (pH 7.4). Afterwards the protein was eluted from the
column by 0.25 M imidazole in PBS (pH 7.4). The protein was degly-
cosylated by Endo HF enzyme (New England Biolabs, USA) for 4–6 h
at room temperature and puriﬁed by size-exclusion chromatography in
PBS on Superdex 75 HiLoad 16/60 column (GE Healthcare, USA).
The protein puriﬁcation was performed using AktaFPLC instrument
(GE Healthcare, USA).
2.2. Surface plasmon resonance (SPR) analysis
Binding analysis was performed using a BIAcore 2000 instrument
(GE Healthcare, USA). Experiments were performed at 25 C with
PBS (pH 7.40) used as a running buﬀer and a ﬂow-rate of 20 ll/min.
The Ig module 2 of FGFR1 was immobilized on the sensor chip
CM5 using an amine coupling kit (GE Healthcare, USA) in three
steps: activation, protein immobilization and blocking. 20 ll of the
activation solution were used for the chip (CM5) activation. Then,
12 ll of 20 lg/ml protein in 10 mM sodium phosphate buﬀer (pH
6.0) were used for immobilization and the chip was blocked by 35 ll
of blocking solution (during immobilization 5 ll/min ﬂow-rate was ap-
plied). For analysis, FGF1 was injected simultaneously into a ﬂow-cell
with the immobilized FGFR Ig2 module and into a control ﬂow-cell
(activated and blocked in the same way as the one used for immobili-
zation) with no protein immobilized. The unspeciﬁc binding was sub-
tracted from the sensorgram, and the resulting curve was used for
analysis.Fig. 1. SPR analysis of the binding between the FGFR Ig2 module
and FGF1. Binding of soluble FGF1 at the indicated concentrations to
the immobilized Ig2 module of FGFR1 is shown. Measurement of the
FGF1 binding at all of the indicated concentrations was performed
nine times.2.3. NMR measurements
The following samples were used for recording of NMR spectra:
15N-labeled 0.1 mM Ig2 module of FGFR1 with or without addition
of 0.05, 0.10 or 0.50 mM FGF1. PBS (pH 7.40) was used as a buﬀer.
The 15N-heteronuclear single quantum correlation (HSQC) spectra
were recorded using the standard set-up provided by ProteinPack.
The spectra were processed by NMRPipe [18] and analyzed by Pron-
to3D [19]. The NMR experiments were performed using Varian Unity
Inova 750 and 800 MHz spectrometers. All spectra were recorded at
25 C.3. Results and discussion
In order to study interaction between the Ig2 module of
mouse FGFR1 and FGF1, the two proteins were produced
in a yeast expression system of P. pastoris and in Escherichia
coli, respectively. The proteins were found to be correctly
folded as judged by one-dimensional NMR analysis.
3.1. SPR analysis of the interaction between FGF1 and Ig
module 2 of FGFR1
To test whether the recombinantly expressed Ig2 module of
FGFR was capable of binding to FGF1, SPR analysis was
used. As appears from Fig. 1, FGF1 was capable of binding
to Ig2 module with a dissociation constant (Kd) of
39 ± 8 nM, which is in agreement with the 65 nM Kd value
for the interaction between the Ig2 module of human FGFR
and FGF1 (determined by isothermal titration calorimetry)
[20], thus giving us evidence that both recombinant proteins
are functionally active. When FGF1 was immobilized, soluble
Ig2 module bound with a Kd value 38 ± 33 nM (data not
shown).
3.2. NMR analysis of the interaction between FGF1 and Ig2
module of FGFR1
Resonance assignment of the mouse Ig2 module of FGFR
has previously been described [10]. It should be noted that
the linker region connecting the C and D b-strands of the
Ig2 module of human FGFR is very ﬂexible in solution and
adopts diﬀerent conformations in the solution [20] and crystal
[11–13] structures of FGFR1. In the mouse Ig2 module of
FGFR1, resonances corresponding to this linker region (resi-
dues 200–213) are completely missing, which could be caused
by either an intermediate exchange between the alternate linker
conformations, enhanced ﬂexibility compared to the human
module, or maybe due to both of these eﬀects.
The interaction between the Ig2 module and FGF1 was
studied by NMR spectroscopy, which allows identiﬁcation of
residues in the vicinity of the binding sites. The 15N-HSQC
spectrum of a 15N-labeled protein records the one bond cou-
pling of the H–N bond, and it can be used as a useful tool
for monitoring site speciﬁc perturbations. The chemical shift
changes of the signals provide a method for identiﬁcation of
the amino acid residues whose NMR signals are perturbed
by the binding of another molecule. 15N-HSQC spectra of
0.1 mM Ig2 module were recorded in the presence of 0, 0.05,
0.1 or 0.5 mM FGF1. Addition of FGF1 led to either line
broadening, chemical shift changes or disappearance of the
NMR signals for certain residues (see Fig. 2). The recorded
changes of chemical shifts after addition of 0.1 and 0.5 mM
FGF1 are shown in Fig. 3. As the highest change of the chem-
ical shift was 0.23 ppm, the residues with the signals disappear-
ing are indicated in Fig. 3 by a 0.3 ppm change of the chemical
Fig. 2. Eﬀect of FGF1 on NMR signals of the FGFR Ig2 module.
15N-HSQC spectra of the representative residues of 0.1 mM 15N-
labeled FGFR Ig2 module in the absence (in red) or presence (in
yellow) of FGF1 at the indicated concentrations are shown. The
spectra in the presence of FGF1 are shown as overlapping the
reference spectrum (in the absence of FGF1).
Fig. 3. Identiﬁcation of the Ig2 modules residues involved in binding
to FGF1. Changes in chemical shifts of 0.1 mM 15N-labeled Ig2
module after addition of 0.10 (A) and 0.5 (B) mM unlabeled FGF1.
The change of the chemical shift was calculated using the following
expression: ((5*DH)^2 + (DN)^2)^0.5, where DH is the change of the
1H chemical shift and DN is the change of the 15N chemical shift. Bars
in diagrams representing chemical shifts 0.3 ppm does not represent
the actual chemical shifts, but correspond to amino acids with
disappeared signals (strongest eﬀect).
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led to disappearance of most the signals, which indicates that
the exchange between the bound and free form of Ig2 module
is intermediate on the NMR time scale. The residues with the
changes of the chemical shifts of greater than 0.1 ppm or com-
pletely disappeared signals after addition of 0.1 mM FGF1
(Fig. 3A) were considered to be signiﬁcantly perturbed. Map-
ping of the signiﬁcantly perturbed residues is shown in Fig. 4,
and as can be seen from the ﬁgure, the perturbed residues
(A167, V168, A170, A171, K172, T173, V174, K175, F176, V220,
V221, G226, T229, Q244, L245, D246, V247, V248, E249) are located
in two clusters on the opposite sides of the module, thus sup-
porting the notion that the Ig2 module has two binding sitesfor FGF. According to the crystal structure of the FGFR-
FGF dimer [11,12], the primary binding site of the Ig2 module
consists of residues L165, A167, P169 and V248, and as can be
seen from Fig. 4A, these residues are located approximately
in the middle of the cluster of residues perturbed by the
FGF1 binding. The secondary site in the crystal structure of
the Ig2 module consists of residues P199, D200, I203, G204,
G205, S219 and V221 [11,12]. Unfortunately, residues P199,
D200, I203, G204 and G205 are located in the ﬂexible part of
the module (C–D linker) whose NMR signals are absent in
the spectrum of the mouse Ig2 module (see above). However,
as can be seen from Fig. 4B, the second cluster of the perturbed
residues is immediately adjacent to the residues of the second-
ary site and partly overlaps it (see Fig. 4B), which indirectly
provides evidence that these residues are involved in binding
to FGF1 in solution. It should be noted that it is not possible
to completely exclude a possibility that binding to one of the
180 deg.
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Fig. 4. Mapping of the residues of the FGFR Ig2 module perturbed by binding to FGF1 onto the modules structure. Blue and magenta – residues of
the Ig2 module perturbed by the FGF1 binding. Magenta – perturbed residues which are also involved in binding to FGF1 as seen in the crystal of
the ternary FGF–FGFR–heparin complex [11–12]. Red – non-perturbed residues which are involved in binding to FGF1 as seen in the crystal.
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protein backbone that results in perturbation of the residues
from the other cluster. If we assume that this is the case, then
binding of FGF1 to just one cluster of the Ig2 module is ex-
pected to aﬀect substantially the backbone conformation for
most of the modules residues, because addition of 0.5 mM
FGF to the module results in disappearance of most of the
modules NMR signals. However, the crystal structures of
the Ig2 module from the ternary FGF–FGFR–heparin com-
plexes are very similar to those from the FGFR not bound
to FGF [11,12], which makes this assumption (that the second
cluster appears due to coincidental rearrangement of the mod-
ules backbone upon binding to the ﬁrst) unlikely.
Thus, we have by NMR obtained direct non-crystallo-
graphic evidence that the Ig2 module of FGFR1 has two dis-
tinct binding sites for FGF1. One of these sites overlaps with
the primary site of the Ig2 module for FGF, and the other
one partly overlaps with the secondary site, which supports
the symmetric model of the ternary FGFR-FGF-heparin com-
plex. Our results are consistent with those of Ibrahimi et al.
[14] who showed that mutations in the secondary site (present
only in the symmetric model) reduced FGF10 signaling and
those of Canales et al. [23] demonstrating that heparin ana-
logues not capable of inducing FGF1 dimerization (as required
by the asymmetric model) can substitute natural heparins in
FGF1 mitogenesis assays.
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